Communiqués Santen Pharmaceutical Co., Ltd.

Actions

4536

JP3336000009

Temps Différé Japan Exchange Autres places de cotation 02:06:35 17/07/2024			Varia. 5j.	Varia. 1 janv.
1 788 ^JPY	+0,82 %		+3,03 %	+27,22 %

09/05	Santen Pharmaceutical Co. (TSE:4536) annonce le rachat de 21 110 000 actions, soit 5,81 %, pour un montant de 38 000 millions de yens.	CI
09/05	Santen Pharmaceutical Co. donne des indications sur le dividende de fin d'année pour l'exercice se terminant le 31 mars 2025	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Santen Pharmaceutical : Announces Status of Share Buyback	01/07	PU
Santen Pharmaceutical : Alesion® Eyelid Cream 0.5%, a new treatment for allergic conjunctivitis, goes on sale in Japan	22/05	PU
Santen Pharmaceutical : Announces Share Buyback	09/05	PU
Santen Pharmaceutical : Reports Fiscal 2023 Consolidated Performance	09/05	PU
Santen Pharmaceutical : Notice of Board of Director and Corporate Auditor Nominations	09/05	PU
Santen Pharmaceutical : and Mitsubishi Tanabe Pharma announce the conclusion of a contract for the joint sales promotion in Japan of Alesion® Eyelid Cream 0.5%, a new treatment for allergic conjunctivitis	07/05	PU
Santen Pharmaceutical : and Bayer Yakuhin Launch Ophthalmic VEGF Inhibitor Eylea®8mg Solution for Intravitreal Injection 114.3 mg/mL	17/04	PU
Santen Pharmaceutical : Positioned for Further Growth in China Following Completion of Vision Park	16/04	PU
Santen Pharmaceutical : obtains manufacturing and marketing approval in Japan for Alesion® eyelid cream (epinastine hydrochloride), a new treatment for allergic conjunctivitis	26/03	PU
Santen Pharmaceutical : Announces Change of Representative Director of the Board	25/03	PU
Santen Pharmaceutical : Announces Cancellation of Treasury Shares	25/03	PU
Santen Pharmaceutical : Announces Completion of Share Buyback	25/03	PU
Santen Pharmaceutical : Announces Status of Share Buyback	01/03	PU
Santen Pharmaceutical : Receives European Commission Approval for Catiolanze® (cationic emulsion of latanoprost 50μg/mL) for Lowering of Intraocular Pressure in Open-Angle Glaucoma and Ocular Hypertension	17/11	PU
Santen Agrees to Licensing Agreements and Asset Transfer for its Pharmaceutical Products in North America	19/07/23	AQ
Harrow Acquires Santen's Branded Ophthalmic Portfolio	19/07/23	AQ
Santen Pharmaceutical Co., Ltd. - Ophthalmic VEGF inhibitor Eylea Solution for Intravitreal Injection 40 mg/mL obtains approval for ROP as sixth indication	27/09/22	AQ
Santen and UBE Received FDA Approval for OMLONTI 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension	27/09/22	AQ
Santen Pharmaceutical : Announces Status of Share Buyback	01/08/22	PU
Santen Pharmaceutical : Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program	22/07/22	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Santen Pharmaceutical Co., Ltd.

Actions

4536

JP3336000009

Communiqués

Filtres